Scientific Presentations

SA1767: Candidate biomarkers of microbiome disruption for patient selection or stratification in clinical trials of microbiome therapeutics in ulcerative colitis (UC)

SA1770: Characterization of IBD microbiomes in models of microbiome disruption and inflammation to evaluate candidate biomarkers for patient selection

Su2009: Pharmacokinetic and Pharmacodynamic (PK & PD) Results from a Randomized, Double, Placebo-Controlled Cohort of a Phase 1b study of Investigational, Oral, Live Biotherapeutic, SER-155, in Adults Undergoing Allo-HCT

Safety and Efficacy Results from a Randomized, Double-blind, Placebo-controlled Cohort 2 of a Phase 1b Study of an Investigational Live Biotherapeutic, SER-155, in Adults Undergoing allo-HCT

Investigational live biotherapeutic SER-155: Biomarker insights from a Phase 1b study in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT)

Pharmacokinetic (PK) and pharmacodynamic (PD) results from a Phase 1b study of SER-155, an investigational, oral, live biotherapeutic evaluated in adults undergoing allogeneic stem cell transplant (allo-HCT)

Identification of key bacterial taxa driving bioactive metabolite production in the gut microbiome using a reverse-translational approach

Quantitative Whole Metagenomic Sequencing (qWMS): a Powerful Tool for Advancing Our Understanding of the Microbiome and its Impact on Health and Disease

Pharmacokinetic (PK) and pharmacodynamic (PD) results from a randomized, double-blind, placebo-controlled Cohort 2 of a Phase 1b study of an investigational, oral, live biotherapeutic, SER-155, in adults undergoing allo-HCT